A new study published in the Journal of Internal and Emergency Medicine provides the first real-world evidence that people switching from cigarettes to the exclusive use of glo, BAT’s heated tobacco product (THP), can significantly reduce both their exposure to certain toxic substances are indicators of potential harm for various smoking-related diseases, compared to continuing to smoke. The results, recorded 6 months after the overall study duration (12 months), showed that the complete switch to glo resulted in statistically significant changes in a range of ‘exposure biomarkers’ (BoEs) and potential indicators. harm, known as ‘biomarkers of potential harm’ (BoPH), compared to those who continue to smoke.
Based on the toxic substances measured, glo users showed: significant reduction of a biomarker for lung cancer risk; significant reduction in white blood cell counts, an inflammatory marker indicative of the risk of cardiovascular disease (CVD) and other smoking-related diseases; improvement in HDL cholesterol associated with a reduced risk of CVD; improvements in two key indicators of lung health; improvement of a key indicator of oxidative stress, a process implicated in several smoking-related diseases, such as cardiovascular disease and hypertension.
David O’Reilly, Director of Scientific Research at BAT, said: ‚ÄúThese are promising results as they allow us to understand the potential reduction in risk that a full switch to glo can bring. The study shows how smokers who switch to glo can reduce their exposure to certain toxic substances, reducing the risk of developing diseases resulting from cigarette smoking. Showing a significant reduction in BOPH amounts, somewhat comparable to quitting smoking completely, is very encouraging and provides further scientific evidence of glo’s health risk reduction potential and how this supports our ambition to build a future. BetterTM by reducing the impact on the health of our company “.
Participants in the study, lasting a total of one year, are British smokers between the ages of 23 and 55 with generally good health with or without the intention of quitting smoking. Smokers who did not want to quit were randomly chosen either to continue smoking cigarettes or to switch to glo only, while smokers who indicated they wanted to quit were given nicotine replacement therapy and access to a termination consultant. A “never smokers” group was also included to serve as a control group that continued to use no tobacco or nicotine products. This study was designed to explore the risk-reducing potential of glo in a real-world rather than a controlled environment. L’ the only intervention was a monthly clinic visit where samples of blood, urine and other measurements were taken. These samples were tested for ‘biomarkers of exposure’ (to selected cigarette smoke toxicants) and ‘biomarkers of potential harm’. Additionally, to ensure compliance, glo groups and those who wanted to quit smoking were tested for the biomarker, CEVal, which indicated whether they had smoked cigarettes recently. Further results of the completed study are expected by the end of 2021 and will determine whether the reduced exposure to toxic substances and biomarkers of potential harm will be maintained throughout the duration of the study. These samples were tested for ‘biomarkers of exposure’ (to selected cigarette smoke toxicants) and ‘biomarkers of potential harm’. Additionally, to ensure compliance, glo groups and those who wanted to quit smoking were tested for the biomarker, CEVal, which indicated whether they had smoked cigarettes recently. Further results of the completed study are expected by the end of 2021 and will determine whether the reduced exposure to toxic substances and biomarkers of potential harm will be maintained throughout the duration of the study. These samples were tested for ‘biomarkers of exposure’ (to selected cigarette smoke toxicants) and ‘biomarkers of potential harm’. Additionally, to ensure compliance, glo groups and those who wanted to quit smoking were tested for the biomarker, CEVal, which indicated whether they had smoked cigarettes recently. Further results of the completed study are expected by the end of 2021 and will determine whether the reduced exposure to toxic substances and biomarkers of potential harm will be maintained throughout the duration of the study. which indicated if they had smoked cigarettes recently. Further results of the completed study are expected by the end of 2021 and will determine whether the reduced exposure to toxic substances and biomarkers of potential harm will be maintained throughout the duration of the study. which indicated if they had smoked cigarettes recently. Further results of the completed study are expected by the end of 2021 and will determine whether the reduced exposure to toxic substances and biomarkers of potential harm will be maintained throughout the duration of the study.

Previous articleTrump or Biden, what changes for the euro? Bloomberg Report
Next articleThe 10 most famous works of art in the world